Exchange: NASDAQ·Updated 07:30 PM EST

OZEM News

News
all
press releases
Eli Lilly’s Orforglipron Wins Big In China – Gains Edge Over Novo In Race For Potential $4.5B Market
Orforglipron, which is marketed as Foundayo, became the first weight-loss pill to receive approval in China, according to a Reuters report.
Stocktwits
Eli Lilly’s Orforglipron Wins Big In China – Gains Edge Over Novo In Race For Potential $4.5B Market
Orforglipron, which is marketed as Foundayo, became the first weight-loss pill to receive approval in China, according to a Reuters report.
Stocktwits
More News
Analyst Justin Patterson said Hims & Hers’ focus on lower treatment prices could eventually attract more subscribers and increase the number of treatments per customer.
Stocktwits
Jefferies said a ‘dynamic GLP-1 environment’ would continue to cause volatility in Hims & Hers’ subscriptions
Stocktwits
CEO Mike Doustdar told CNBC that while the company has experienced weak growth in the past due to pricing, volumes have grown ‘phenomenally.’
Stocktwits
LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook.
Stocktwits
Lilly raised its full-year revenue forecast to $91-92 billion, compared with its previous outlook of $85-87 billion.
Stocktwits
Retatrutide helped patients with type 2 diabetes lose an average of 44 to 47 pounds over 80 weeks, compared with about 21 pounds for Ozempic.
Stocktwits
European Medicines Agency’s advisory committee recommended approval of its once-daily weight-loss pill, Foundayo.
Stocktwits
Viking is set to begin two simultaneous studies of VK2735 in a Phase 3 trial after Phase 2 showed weight reductions of up to 12.2% after 13 weeks.
Stocktwits
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Zacks

Advertisement|Remove ads.